Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

A glimpse at Big Pharma’s upper echelon in the first three quarters of 2023

By Brian Buntz | November 3, 2023

Leadership banner concept with paper boat on blackboard background. One leader ship leads others

[tomertu/Adobe Stock]

In 2023, demand for GLP-1 receptor agonists such as Lilly’s tirzepatitde and Novo Nordisk’s semaglutide surged just as demand for COVID-19 therapies waned. As a result, Novo Nordisk had 33% growth at constant exchange rates over the first nine months of the year. Similarly, Lilly experienced a 37% jump in revenue in the third quarter, with strong sales of Mounjaro (tirzepatitde) helping lead the way.

Below is a roundup of the year-to-date revenue for several Big Pharma companies that have publicly shared third-quarter financial data. For J&J and Roche, the companies’ non-pharma sales were excluded. Merck’s figures also include sales from its veterinary business.

Merck having a banner year

Given all of the attention GLP-1 drugs have received in 2023, Merck's robust performance may be easy to overlook. In August, it raised its sales guidance. And in its third-quarter earnings announcement, the company announced that it had raised its full-year revenue guidance to $59.7-$60.2 billion, equating to 11% to 12% underlying growth, excluding the COVID-19 antiviral Lagevrio sales and foreign exchange considerations. Demand remains strong for the oncology blockbuster Keytruda. In the third-quarter, the drug's sales grew 17% to $6.3 billion, thanks in part to expanded use in earlier-stage cancers like lung, breast, and bladder. In the third-quarter, Keytruda sales were up 17% thanks to continued uptake in lung, breast, bladder and other cancers.

Sales of the HPV vaccine Gardasil were also brisk. The company aims for the vaccine to hit $11 billion in sales by 2030.

The megablockbuster Keytruda has been a cash cow for Merck since it debuted in 2014. But the initial patent for Keytruda is set to expire in 2028. The company has filed for several additional patents that extend exclusivity into 2040. The most recent patents granted don't expire until 2036, giving Keytruda some cushion IP protection.

In its recent earnings call, Merck execs noted the company expects to sustain its oncology leadership for the next decade based on Keytruda’s broad label and enduring efficacy across lines of therapy. The recent antibody-drug-conjugate collaborations with Daiichi Sankyo and Kelun Biotech further bolster the company's capabilities in oncology.

Pfizer faces eroding demand for COVID-19 therapies

In the third quarter, Pfizer announced that its revenues were down 41% operationally year-over-year as a result of reduced demand for the company's COVID-19 vaccine and Paxlovid antiviral. "We have rebased our COVID expectations, and now I think it's very easy for everyone to be able to model what I think will be stable COVID revenues going forward," said CEO Albert Bourla in an earnings call. The decline of the COVID-19 products is not new. Flagging demand for the segment contributed to notable stock declines at the mid-year point as well.

Outside of its COVID-19 products, however, the firm saw 10% operational revenue growth compared to Q3 2022. The firm noted that growth drivers include the new RSV vaccine Abrysvo, Vyndaqel for transthyretin amyloid cardiomyopathy, and Prevnar pneumococcal vaccines.

To boost its operational efficiency, the company has announced a restructuring program targeting at least $3.5 billion in net cost savings by end of 2024.

Bourla notes that the company's RSV vaccine, Abrysvo, has "exceeded our expectations." He noted that the company was aiming to ride on "the coattails of flu vaccinations," which are typically high in September and October. "We have about a 70% co-administration rate," Bourla said. He also highlighted the potential of combination products that could combine vaccines for different diseases, such as COVID, flu, and RSV, into a single injection.

 


Filed Under: Drug Discovery and Development, Metabolic disease/endicrinology, Oncology
Tagged With: Big Pharma, COVID-19 therapy demand, GLP-1 agonists, pharma industry trends, Pharmaceutical Revenue
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE